Suggestions
Amy Cray
Champion for Extraordinary People. Mover, seeker.
Amy Cray is a strategic counsel and thought partner who excels in collaborating with visionary leaders and dynamic teams to actualize groundbreaking concepts. With a wealth of global experience, Amy has provided support to high-achieving individuals facing intricate challenges across various domains. As a trusted advisor from day one, she has navigated through pivotal moments in their lives. Amy's diverse skill set encompasses expertise in company development, fostering inclusive cultures, organizational management, public relations, human resources, real estate, interior design, creative production, hospitality, food and wine, and overseeing private estates. By simplifying complexities, fostering creativity, guiding through crises, and crafting motivating environments, Amy enhances executive performance. She values curiosity, humility, kindness, and a drive to make a lasting impact. Additionally, Amy is a songwriter, language enthusiast, and an avid traveler who appreciates life's varied thrills.
Highlights
Bloomberg offered an absolute slash and burn piece on the actionability of genetic profiling recently, pointing a (middle) finger at companies like 23andme, which is struggling while waiting for the science and medical establishment to catch up in order to prove out its promise and value.
Rather than highlighting the normative struggle in biotech - the difficulty in maintaining adequate runway while developing and embracing budding and novel therapeutics in a humongous industry amid broad market fluctuations and the effects of policy, it claimed that 23andme’s current situation is proof that the revolution/revelation that genomic medicine proponents insist is en route is a big ole lie, and further, understanding the specific makeup of one’s own genome is neither appropriate nor relevant in improving outcomes, and is rather just another snake oil being peddled by the inflated egos of out-of-touch tech billionaires in order to profit off the dumb masses.
Biotech is a TERRIBLY tricky industry. You are trying to move absolute mountains, and sometimes you don’t get lucky, or hire the right team, and sometimes you simply run out of money because your idea is way ahead of its time. It doesn’t mean you’re wrong. It might actually mean you’re very, very right. This industry is NEW by the standards of medicine. We have to get comfy with not knowing what we don’t yet know, rather than slapping an expiration date on it and crying like a Karen.
Today a group of badasses at Mass General published published findings of a specific gene whose expression fully mediates metastatic cancer cell growth (which causes 90% of cancer-related death), so I will stop cursing Bloomberg in my head and laugh at them instead. Care to join?
